New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
10:00 EDTVECO, SNN, ITRI, EXXI, SCOR, ZTS, TRIP, ROLL, SGNT, SGEN, BUD, WCN, TCBK, PES, CROX, CNVR, SBMRYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Itron (ITRI) upgraded to Buy from Hold at Needham... Pioneer Energy (PES) upgraded to Buy from Speculative Buy at Global Hunter... RBC Bearings (ROLL) upgraded to Buy from Neutral at BofA/Merrill... Smith & Nephew (SNN) upgraded to Buy from Hold at Deutsche Bank... Sprint (S) upgraded to Buy from Hold at Deutsche Bank... TriCo Bancshares (TCBK) upgraded to Strong Buy from Outperform at Raymond James... TripAdvisor (TRIP) upgraded to Outperform from Sector Perform at RBC Capital... Veeco (VECO) upgraded to Outperform from Neutral at Credit Suisse... Waste Connections (WCN) upgraded to Buy from Hold at BB&T... Zoetis (ZTS) upgraded to Outperform from Market Perform at William Blair... SABMiller (SBMRY) upgraded to Conviction Buy from Buy at Goldman... AB InBev (BUD) upgraded to Buy from Sell at Goldman... comScore (SCOR) upgraded at Northland Securities... Conversant (CNVR) upgraded to Buy from Hold at Craig-Hallum... Seattle Genetics (SGEN) upgraded to Buy from Hold at Needham... Energy XXI (EXXI) upgraded to Buy from Accumulate at KLR Group... Crocs (CROX) upgraded to Overweight from Neutral at Piper Jaffray... Sagent Pharmaceuticals (SGNT) upgraded to Outperform at RBC Capital.
News For ITRI;PES;ROLL;SNN;TCBK;TRIP;VECO;WCN;ZTS;SBMRY;BUD;SCOR;CNVR;SGEN;EXXI;CROX;SGNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2015
15:29 EDTSBMRYDiageo drops nearly 5% following WSJ report of excess inventory shipments
Subscribe for More Information
15:04 EDTTRIPNotable companies reporting after market close
Subscribe for More Information
14:38 EDTTRIPTripAdvisor July weekly 93 straddle priced for 8% movement into Q2
12:13 EDTTRIPTripAdvisor technical notes ahead of earnings
Subscribe for More Information
06:50 EDTSBMRYSABMiller reports Q1 group NPR up 3%
Subscribe for More Information
July 22, 2015
13:33 EDTTRIPTripAdvisor July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
July 21, 2015
16:25 EDTZTSZoetis files automatic mixed securities shelf
Subscribe for More Information
10:01 EDTBUDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:01 EDTBUDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:01 EDTSBMRYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ASML (ASML) upgraded to Accumulate from Neutral at SNS Securities... Anacor (ANAC) upgraded to Buy from Neutral at Goldman... Artisan Partners (APAM) upgraded to Outperform from Neutral at Credit Suisse... Canadian National (CNI) upgraded to Buy from Hold at Canaccord... General Mills (GIS) upgraded to Outperform from Sector Perform at RBC Capital... Halliburton (HAL) upgraded to Accumulate from Neutral at Global Hunter... Harte-Hanks (HHS) upgraded to Outperform from Market Perform at BMO Capital... MDC Partners (MDCA) upgraded to Overweight from Neutral at Piper Jaffray... SABMiller (SBMRY) upgraded to Buy from Neutral at Nomura... Sanmina (SANM) upgraded to Neutral from Underperform at Longbow... Santander Mexico (BSMX) upgraded to Neutral from Sell at Goldman... Sherwin-Williams (SHW) upgraded to Buy from Neutral at Northcoast... Southwestern Energy (SWN) upgraded to Buy from Neutral at Global Hunter... Verisk Analytics (VRSK) assumed with an Outperform at Keefe Bruyette.
08:34 EDTTRIPTripAdvisor shares should be bought on any weakness, says Oppenheimer
Oppenheimer is upbeat on the 2H15 outlook for online travel, due partly to what it says are higher inventories, improving site traffic, and a solid industry backdrop. The firm says that TripAdvisor's site traffic is accelerating, while its mobile conversions appear to be improving. Consequently, the firm is more confident that the company's hotel inventory is selling well. Oppenheimer introduced a $105 price target on TripAdvisor and reiterated an Outperform rating on the name.
06:58 EDTZTSZoetis added to US 1 List at BofA/Merrill
05:26 EDTBUDAB InBev downgraded to Neutral from Buy at Nomura
Subscribe for More Information
05:25 EDTSBMRYSABMiller upgraded to Buy from Neutral at Nomura
Nomura upgraded SABMiller to Buy citing an attractive risk/reward following the recent underperformance of shares.
July 20, 2015
16:43 EDTBUDAB InBev initiated with a Buy at Sterne Agee CRT
Subscribe for More Information
11:33 EDTBUDAB InBev downgraded to Neutral from Buy at Nomura
08:39 EDTITRIItron weakness a buying opportunity, says Baird
Subscribe for More Information
08:38 EDTZTSAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:30 EDTZTSZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information
05:48 EDTTRIPTripAdvisor price target raised to $100 from $92 at Ascendiant
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use